Position in ZYME
as of Mar 31, 2026
· filed May 22, 2026
Position Value
$1,144,979
New position
Shares Held
45,726
first reported quarter
Ownership
0.063%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026SEGALL BRYANT & HAMILL, LLC holds $242,312,554 across 27 Biotechnology names. ZYME ranks #21 (0.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PTGX |
Protagonist Therapeutics, Inc
|
212,714 | $22,420,055 | |
| 2 | TECH |
BIO-TECHNE Corp
|
428,507 | $22,393,775 | |
| 3 | KRYS |
Krystal Biotech, Inc.
|
79,497 | $20,535,665 | |
| 4 | HALO |
Halozyme Therapeutics, Inc.
|
298,056 | $19,263,359 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
38,073 | $17,001,117 | |
| 6 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
31,870 | $16,682,988 | |
| 7 | MIRM |
Mirum Pharmaceuticals, Inc.
|
175,898 | $16,249,457 | |
| 8 | PTCT |
Ptc Therapeutics, Inc.
|
195,380 | $13,311,239 |
All Filings in ZYME
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,144,979 | 45,726 | Shares | Sole | 2026-05-22 | |
| No filing history on record for this holder in this stock. | ||||||